The Polypill: From Promise to Pragmatism

PLoS Medicine

Volumn 12, Issue 8, 2015, Pages

  Huffman, Mark D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; ATORVASTATIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAMIPRIL; SIMVASTATIN; CARDIOVASCULAR AGENT;

ACCURACY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COUGHING; EVIDENCE BASED PRACTICE; HEALTH BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INTERNAL CONSISTENCY; MEDICATION THERAPY MANAGEMENT; META ANALYSIS (TOPIC); MYALGIA; PILL; POLYPILL; PRACTICE GUIDELINE; CARDIOVASCULAR DISEASES; FOOD AND DRUG ADMINISTRATION; MEDICATION COMPLIANCE; PRIMARY PREVENTION; PROCEDURES; SECONDARY PREVENTION; UNITED STATES;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICATION ADHERENCE; PRIMARY PREVENTION; SECONDARY PREVENTION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84940765137     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001862     Document Type: Article

References (21)

1. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH, Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007; 120(8):713–9 17679131
2. World Health Organization, Wellcome Trust. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. Geneva, 2002. http://whqlibdoc.who.int/hq/2002/WHO_MPN_CVD_2002.01.pdf?ua=1. Accessed July 10, 2015. WHO Report.
3. Wald NJ, Law MR, A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326:1419. 12829553
4. Capewell S, Graham H, Will cardiovascular disease prevention widen health inequalities? PLoS Medicine. 2010; 7(8):e1000320. doi: 10.1371/journal.pmed.1000320 20811492
5. de Cates AN, Farr MR, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014; 4:CD009868. doi: 10.1002/14651858.CD009868.pub2 24737108
6. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a Fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of cardiovascular disease: The UMPIRE randomized clinical trial. JAMA. 2013; 310(9):918. doi: 10.1001/jama.2013.277064 24002278
7. Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernandez Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence. J Am Coll Cardiol. 2014; 64(20):2071–82. doi: 10.1016/j.jacc.2014.08.021 25193393
8. Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2014; 22:920–930. doi: 10.1177/2047487314530382 24676715
9. Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014; 348:g3318–8. doi: 10.1136/bmj.g3318 24868083
10. Huffman MD, Perel P, Castellano JM, Fuster V, Rodgers A, Webster R, et al. An application to recommend that fixed-dose combination therapy be added to the WHO model list of essential medicines for secondary prevention of cardiovascular disease (ischemic heart disease and ischemic stroke). http://www.who.int/selection_medicines/committees/expert/20/applications/Aspirin_FDC.pdf?ua=1. Accessed 27 May 2015.
11. Webster R, Patel A, Billot L, Cass A, Burch C, Neal B, et al. Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: The SPACE Collaboration. Int J Cardiol. 2013; 170(1):30–5. doi: 10.1016/j.ijcard.2013.10.007 24144927
12. Huffman MD, Yusuf S, Polypills: essential medicines for cardiovascular disease secondary prevention? J Am Coll Cardiol. 2014; 63(14):1368–70. doi: 10.1016/j.jacc.2013.08.1665 24561141
13. Fontana M, Asaria P, Moraldo M, Finegold J, Hassanally K, Manisty CH, et al. Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility. Circulation. 2014; 129: 2539–46. doi: 10.1161/CIRCULATIONAHA.113.007595 24744274
14. Working Group on the Summit on Combination Therapy for CVD. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J. 2014; 35(6):353–64. doi: 10.1093/eurheartj/eht407 24288261
15. Viera AJ, Sheridan SL, Edwards T, Soliman EZ, Harris R, Furberg CD, Acceptance of a polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med. 2011 Jan;52(1):10–5. doi: 10.1016/j.ypmed.2010.09.016 20933538
16. Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25 Suppl 2):S49–73. doi: 10.1161/01.cir.0000437741.48606.98 24222018
17. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SCJ, Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301(8):831–41. doi: 10.1001/jama.2009.205 19244190
18. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults. JAMA. 2013; 311: 507–20.
19. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011; 365(22):2088–97. doi: 10.1056/NEJMsa1107913 22080794
20. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014; 11:CD000011. doi: 10.1002/14651858.CD000011.pub4 25412402
21. Fenn J, LeHong H, Hype cycle for emerging technologies, 2011. Gartner. 2011.